186,649 research outputs found
Could maternal stress increase the risk of developing psoriasis in the offspring?
No full textVery few data exist on the role of prenatal stress as a risk factor for psoriasis. As reported in this issue of the BJD, the impressive findings of the study by Xiaoqin Liu et al. from Aarhus University in Denmark show that prenatal exposure to severe maternal stress increases the risk of developing psoriasis in the offsprin
Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
No full textPaolo Gisondi, Giampiero Girolomoni Department of Medicine, Section of Dermatology and Venereology, University of Verona, Verona, Italy Abstract: Chronic plaque psoriasis presents clinically as an inflammatory disease of the skin, which is often associated with comorbidities and responsible for a poor quality of life. It can widely vary among patients because of different age of onset, type of symptoms, areas of involvement, and disease severity. The choice of the treatment of psoriasis should be person­alized according to the specific needs of the patients. Apremilast is a well-tolerated and effective phosphodiesterase type 4 inhibitor that is indicated for the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis. In this article, the pharmacological, clinical, and safety aspects of apremilast are reviewed. Based on these data, apremilast could be indicated for patients with a Psoriasis Area and Severity Index score <10 but with a significant impact on quality of life and seems to be an appropriate treatment for elderly patients also. Keywords: psoriasis, apremilast, therapy, psoriasis severit
Stevenia gilasiani sp. nov. (Diptera: Rhinophoridae): the first woodlouse fly with male sexual-patches
No full textStevenia gilasiani Ziegler, Gisondi & Cerretti, sp. nov. from western Iran is described and illustrated. Cladistic arguments are provided in order to give an explicit genus level affiliation for the new species. Stevenia gilasiani sp. nov. is the first rhinophorid characterized by male ventral sexual-patches on abdominal tergites 3, 4 and 5 and sternites 3 and 4, and is the only Stevenia characterized by two postpronotal setae instead of usual three. A comparison with all congeners is made
Is the routine screening for hyperhomocysteinaemia recommended in patients with chronic plaque psoriasis?
No full textIs the routine screening for hyperhomocysteinaemia recommended in patients with chronic plaque psoriasis
Therapeutic insights from the British Association of Dermatologists Biologic Interventions Register
No full textInsights in the value of epidemiology for skin diseases toda
Recognizing the differential impact of site of involvement on quality of life in dermatology
No full textLinked Article: Augustin et al. Br J Dermatol 2019; 181:358-365
Cardiometabolic Comorbidities and the Approach to Patients with Psoriasis
No full textPsoriasis is a chronic inflammatory, immune-mediated skin disease, which may cause significant deterioration in the quality of life. Recent evidence indicates that psoriasis and psoriatic arthritis are frequently associated with cardiometabolic diseases including myocardial infarction, stroke, diabetes, obesity, dyslipidemia and non-alcoholic fatty liver disease. Although the causal relationship between cardiometabolic comorbidities and psoriasis has not yet been completely proven, it appears that obesity is a relevant risk factor for the development of psoriasis and metabolic syndrome. In addition, moderate to severe psoriasis itself is a risk factor for cardiovascular disease and the metabolic syndrome. Some common genetic traits as well as inflammatory mechanisms may underlie the development of psoriasis and cardiometabolic comorbidities. The presence of comorbidities has important implications in the global approach to patients with psoriasis. Traditional systemic anti-psoriatic agents could negatively affect cardiometabolic comorbidities, and may have important interactions with drugs commonly used by psoriasis patients. In contrast, the recent findings that the risk of myocardial infarction is markedly reduced in rheumatoid arthritis patients who respond to anti-TNF-alpha therapy compared with non-responders supports the hypothesis that the anti-inflammatory effect of TNF-alpha blockers might potentially reduce the cardiovascular risk also in psoriasis patients. Finally, patients with moderate to severe psoriasis should be treated promptly and effectively, should also be encouraged to drastically correct their modifiable cardiovascular risk factors, in particular obesity and smoking habit
Does systemic treatment of psoriasis reduce the risk of comorbidities?
No full textIn this issue of the BJD, Neil Korman has published an interesting review article presenting the evidence supporting psoriasis as a systemic disease. He also discusses new psoriasis treatment paradigms, which may potentially reduce the effects of systemic inflammation and consequently prevent or reverse comorbidities.1 Optimizing patient outcomes beyond clearing the skin, such as reducing the risk of cardiovascular diseases, is crucially relevant for our clinical practice. In this commentary, the pathogenesis behind the comorbidities and whether systemic treatment of psoriasis could reduce the risk of comorbidities by damping systemic inflammation will be discussed
- …
